A small molecule inverse agonist for the human thyroid-stimulating hormone receptor

Area of Science:

• Endocrinology and Pharmacology
• Molecular Biology
• Drug Discovery

Background:

• Basal signaling of the TSH receptor (TSHR) plays a role in thyroid cancer and hyperthyroidism.
• Small molecule inverse agonists are potential therapeutic agents and research tools for TSHR.

Purpose of the Study:

• To discover and characterize the first small-molecule inverse agonist for the TSH receptor.
• To evaluate its potential for inhibiting both basal and stimulated TSHR signaling.

Main Methods:

• Synthesis and characterization of a novel quinazolinone derivative (Compound 1).
• In vitro assays measuring cAMP production in HEK-EM 293 cells expressing wild-type and mutant TSHRs.
• Assessment of Compound 1's effect on TSHR signaling and gene expression in primary human thyrocytes.

Main Results:

• Compound 1 demonstrated inverse agonist activity at TSHR, inhibiting basal and TSH-stimulated cAMP production.
• It competitively antagonized TSH-mediated signaling and inhibited basal signaling in wild-type and mutant TSHRs.
• Compound 1 reduced basal mRNA levels of key thyroid-related genes in human thyrocytes.

Conclusions:

• Small, drug-like molecules can effectively inhibit basal TSHR signaling.
• Compound 1 serves as a lead compound for developing potent inverse agonists for TSHR research and therapy.